These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11299547)

  • 1. ICAAC eyes PIs, NNRTIs, and STIs.
    Mascolini M
    IAPAC Mon; 2000 Dec; 6(12):362-75. PubMed ID: 11299547
    [No Abstract]   [Full Text] [Related]  

  • 2. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
    Espiau M; Soler-Palacín P; Borrull A; Figueras C
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
    [No Abstract]   [Full Text] [Related]  

  • 4. Lopinavir/r versus nelfinavir as salvage therapy.
    Resino S; Alvaro-Meca A; de José MI; Gurbindo MD; Ramos JT; Martin-Fontelos P; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2005 Apr; 24(4):392-3. PubMed ID: 15818313
    [No Abstract]   [Full Text] [Related]  

  • 5. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
    Chan-Tack KM; Edozien A
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):531-2. PubMed ID: 16652066
    [No Abstract]   [Full Text] [Related]  

  • 6. [Protease inhibitors].
    Tachikawa N
    Kansenshogaku Zasshi; 2005 Dec; 79(12):905-30. PubMed ID: 16444973
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiviral update.
    PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newest protease inhibitor Kaletra has a unique profile.
    Murphy MJ
    HIV Clin; 2001; 13(1):6-7. PubMed ID: 11810817
    [No Abstract]   [Full Text] [Related]  

  • 9. [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].
    Valencia-Ortega ME; Moreno-Celda V
    Enferm Infecc Microbiol Clin; 2008 Dec; 26(10):671-2. PubMed ID: 19100200
    [No Abstract]   [Full Text] [Related]  

  • 10. The daunting challenge of keeping HIV suppressed.
    Cohen J
    Science; 1997 Jul; 277(5322):32-3. PubMed ID: 9229768
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 16. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
    Spear GT; Olinger G; Sullivan BL; Landay AL; Kessler H; Connick E; Kuritzkes D; St Clair M; Spritzler J; Wu H; Lederman MM
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1713-5. PubMed ID: 10606095
    [No Abstract]   [Full Text] [Related]  

  • 17. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
    Delaugerre C
    Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
    [No Abstract]   [Full Text] [Related]  

  • 18. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 19. [The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
    Duval X
    Presse Med; 2000 Feb; 29(5):253-6. PubMed ID: 10701407
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
    Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.